Eli Lilly and Company $LLY Shares Bought by Greenspring Advisors LLC

Greenspring Advisors LLC raised its holdings in Eli Lilly and Company (NYSE:LLY) by 508.2% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,041 shares of the company’s stock after purchasing an additional 2,541 shares during the period. Greenspring Advisors LLC’s holdings in Eli Lilly and Company were worth $3,269,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in LLY. Cidel Asset Management Inc. raised its position in shares of Eli Lilly and Company by 26.5% during the 3rd quarter. Cidel Asset Management Inc. now owns 26,726 shares of the company’s stock valued at $20,392,000 after acquiring an additional 5,591 shares in the last quarter. Spire Wealth Management raised its position in shares of Eli Lilly and Company by 2.2% during the 4th quarter. Spire Wealth Management now owns 27,719 shares of the company’s stock valued at $29,789,000 after acquiring an additional 592 shares in the last quarter. Coldstream Capital Management Inc. raised its position in shares of Eli Lilly and Company by 25.6% during the 3rd quarter. Coldstream Capital Management Inc. now owns 42,418 shares of the company’s stock valued at $32,365,000 after acquiring an additional 8,659 shares in the last quarter. Farther Finance Advisors LLC raised its position in shares of Eli Lilly and Company by 30.8% during the 4th quarter. Farther Finance Advisors LLC now owns 31,145 shares of the company’s stock valued at $33,471,000 after acquiring an additional 7,338 shares in the last quarter. Finally, Teachers Retirement System of The State of Kentucky raised its position in shares of Eli Lilly and Company by 3.5% during the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 165,165 shares of the company’s stock valued at $126,022,000 after acquiring an additional 5,595 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have commented on the company. Cantor Fitzgerald lifted their target price on Eli Lilly and Company from $1,205.00 to $1,230.00 and gave the company an “overweight” rating in a research note on Friday, May 1st. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $1,285.00 target price on shares of Eli Lilly and Company in a research note on Friday, March 6th. Berenberg Bank raised their target price on Eli Lilly and Company from $950.00 to $1,050.00 and gave the company a “hold” rating in a research note on Thursday, February 19th. Loop Capital set a $1,200.00 target price on Eli Lilly and Company in a research note on Tuesday, February 10th. Finally, BMO Capital Markets reiterated an “outperform” rating and issued a $1,300.00 target price on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $1,227.00.

Eli Lilly and Company Price Performance

Shares of LLY opened at $1,081.34 on Thursday. The firm has a market capitalization of $1.02 trillion, a price-to-earnings ratio of 38.41, a price-to-earnings-growth ratio of 1.16 and a beta of 0.53. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,149.10. The stock’s fifty day moving average is $965.78 and its 200-day moving average is $1,011.48.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The company had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company’s quarterly revenue was up 55.5% compared to the same quarter last year. During the same period last year, the company earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities analysts anticipate that Eli Lilly and Company will post 35.8 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, May 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is 24.58%.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly expanded its pipeline with a $1.9 billion partnership with Ascidian Therapeutics focused on kidney disease treatments, reinforcing management’s strategy of using obesity cash flow to fund acquisitions and diversify beyond GLP-1 drugs. Eli Lilly, Ascidian Sign $1.9 Billion Kidney-Disease Treatment Deal
• Positive Sentiment: Lilly reported encouraging clinical updates for its obesity and immunology pipeline, including progress in the TRIUMPH-1 retatrutide study and a pediatric ulcerative colitis trial for mirikizumab, both of which support longer-term growth expectations. Lilly’s TRIUMPH-1 Retatrutide Trial Reaches Key Milestone in Obesity Drug Race Lilly’s Pediatric Ulcerative Colitis Trial Marks Key Step for Mirikizumab Growth
• Positive Sentiment: Coverage news also remained favorable, with CVS Caremark and other major pharmacy benefit managers broadening access to Lilly’s obesity portfolio, which should improve prescription volume for Zepbound and Foundayo. Eli Lilly Wins Back CVS Health, Reverting Novo’s Advantage

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.